Halozyme Therapeutics (HALO) after record results and higher guidance: is the stock still undervalued?
FROM THE WIRE · FINANCE.YAHOO.COM
Halozyme Therapeutics (HALO) just posted third quarter 2026 results that featured record revenue of US$492.97 million and net income of US$247.05 million, along with higher full year guidance and ongoing Merck litigation. The latest numbers come after a powerful run in Halozyme…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralRecord results and higher guidance, but the stock already pulled back this week and the Merck litigation remains open.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Halozyme posted record third quarter 2026 revenue of US$492.97 million.
- 02Net income was US$247.05 million, and full year guidance was raised.
- 03The stock slipped 5.66% over the last day and 6.07% over the past week.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Halozyme Therapeutics, Inc.104.15 USD-0.52%today -15.29%Neutral Merck & Co., Inc.147.13 USD+0.31%today +0.13%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets